Polymorphisms within Genes Coding for IL-17A and F and Their Receptor as Clinical Hallmarks in Ankylosing Spondylitis
Table 3
The distribution of (a) IL-17A and IL-17F and (b) IL-17RA and IL-17R genotypes with respect to clinical parameters of ankylosing spondylitis patients.
(a)
IL-17A rs2275913
IL-17F rs763780
GG
GA
AA
AA
AG
Median (IQR)
Median (IQR)
Median (IQR)
Median (IQR)
Median (IQR)
CRP 0 m.
43
13.99 (7.06-47.09)
54
18 (6.983-38.86)
11
15.3 (7.85-33)
97
18.33 (7.825-39.27)
11
9.38 (5-16.73)
CRP 3 m.
30
10.11 (1.39-21.12)
40
5.1 (1.325-10.08)
9
2.6 (0.95-7.9)
71
6.2 (1.52-13.55)
8
1.3 (0.375-11.84)
CRP 6 m.
25
7.06 (0.8-12.67)
39
5.41 (0.9-15.6)
8
3.35 (0.9-9.758)
64
5.71 (1.55-13.22)
8
1.1 (0.35-19.76)
VAS 0 m.
48
87 (80-90)(a)
70
80 (70-90)
14
80 (70-90)
122
80 (72.5-90)(b)
10
88.5 (84.5-92.5)
VAS 3 m.
50
35 (24.5-40)
74
30 (29.5-40)
14
30 (25-30)
127
30 (27-40)
11
30 (22-35)
VAS 6 m.
47
20 (10-29)
71
20 (15-29)
13
20 (16-23.5)
120
20 (14.25-25)
11
20 (11-30)
BASDAI 0 m.
50
7.95 (7-9)
74
7.95 (6.775-8.6)
14
8.3 (6.375-9)
127
8 (6.8-8.8)
11
8.6 (7-9)
BASDAI 3 m.
50
3.275 (2.744-4.1)
74
3.2 (2.65-3.94)
14
3 (2.8-3.063)
127
3.2 (2.75-4)
11
3 (2.725-3.3)
BASDAI 6 m.
48
2.35 (1.925-2.8)
71
2.25 (2-2.7)
13
2 (2-2.825)
121
2.15 (2-2.7)(c)
11
2.5 (2.3-2.9)
(b)
IL-17RA rs4819554
IL-17RC rs708567
AA
AG
GG
AA
AG
GG
Median (IQR)
Median (IQR)
Median (IQR)
Median (IQR)
Median (IQR)
Median (IQR)
CRP 0 m.
63
16.93 (6.9-39.11)
41
18.46 (7.825-42.09)
4
9.62 (9.248-25.34)
32
14.8 (6.928-28.73)
54
18.4 (8.29-45.73)
22
14.12 (7.17-33.51)
CRP 3 m.
46
5.745 (1.3-13.78)
31
6.54 (1-12.27)
2
5.51 (1.52-9.5)
26
2.15 (0.675-10.53)(g)
40
9.46 (2.55-14.79)
13
3 (0.9-9.555)
CRP 6 m
44
6.49 (0.75-18.33)
26
4.655 (2.05-12.07)
2
5 (3.8-6.2)
23
3.6 (0.7-12.88)
34
6.06 (1.35-13.37)
15
4.2 (2-15.94)
VAS 0 m.
80
80.5 (80-90)
46
80 (70-90)
6
84.5 (68.25-91.25)
39
80 (70-90)
65
81 (79-90)
28
84 (76-90)
VAS 3 m.
83
30 (23-40)(d)
49
35 (30-40)
6
38 (25-46.25)
41
30 (25-38.5)
68
30 (26.5.5-40)
29
35 (30-40)
VAS 6 m.
81
20 (10-23.5)(e)
45
20 (20-30)
5
21 (15-35)
40
20 (11.25-26.5)
62
20 (15-25)
29
20 (10-30)
BASDAI 0 m.
83
8 (7-8.8)
49
7.9 (6.6-8.95)
6
8.213 (6.675-9.25)
41
7.8 (6.1-8.6)
68
7.95 (7-8.8)
29
8.2 (7.4-9)
BASDAI 3 m.
83
3.1 (2.55-3.7)
49
3.325 (3-4)
6
3.3 (1.975-4.2)
41
3 (2.175-3.95)
68
3.2 (3-4)
29
3.2 (2.5-3.9)
BASDAI 6 m.
81
2.1 (1.925-2.6)(f)
46
2.375 (2-2.8)
5
2.3 (1.45-2.9)
40
2.2 (2-2.5)
63
2.25 (2-2.8)
29
2.3 (1.95-2.8)
(a)GG vs. GA+AA, ;GG vs. GA, ;GA vs. GG+AA, ;(b)AA vs. AG, ;(c)AA vs. AG, ;(d)AA vs. AG+GG, ;AA vs. AG, ;AA+GG vs. AG, ;(e)AA vs. AG+GG, ;AA vs. AG, ;AA+GG vs. AG, ; (f) AA vs. AG+GG, ;AA vs. AG, ;AA+GG vs. AG, ;(g)AA vs. AG+GG, ;AA vs. AG, ;AA+GG vs. AG, .: number of patients in groups; IQR: interquartile range; CRP: C-reactive protein; VAS: visual analogue scale; DAS28: disease activity score 28; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; 0 m.: at the baseline; 3 m.: after 3 months of therapy; 6 m.: after 6 months of treatment.
